Cargando…

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients

OBJECTIVE: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients. METHODS: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF...

Descripción completa

Detalles Bibliográficos
Autores principales: Lennol, Matthew Paul, Sánchez-Domínguez, Irene, Cuchillo-Ibañez, Inmaculada, Camporesi, Elena, Brinkmalm, Gunnar, Alcolea, Daniel, Fortea, Juan, Lleó, Alberto, Soria, Guadalupe, Aguado, Fernando, Zetterberg, Henrik, Blennow, Kaj, Sáez-Valero, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628034/
https://www.ncbi.nlm.nih.gov/pubmed/36324176
http://dx.doi.org/10.1186/s13195-022-01108-2
_version_ 1784823105719369728
author Lennol, Matthew Paul
Sánchez-Domínguez, Irene
Cuchillo-Ibañez, Inmaculada
Camporesi, Elena
Brinkmalm, Gunnar
Alcolea, Daniel
Fortea, Juan
Lleó, Alberto
Soria, Guadalupe
Aguado, Fernando
Zetterberg, Henrik
Blennow, Kaj
Sáez-Valero, Javier
author_facet Lennol, Matthew Paul
Sánchez-Domínguez, Irene
Cuchillo-Ibañez, Inmaculada
Camporesi, Elena
Brinkmalm, Gunnar
Alcolea, Daniel
Fortea, Juan
Lleó, Alberto
Soria, Guadalupe
Aguado, Fernando
Zetterberg, Henrik
Blennow, Kaj
Sáez-Valero, Javier
author_sort Lennol, Matthew Paul
collection PubMed
description OBJECTIVE: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients. METHODS: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. RESULTS: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. CONCLUSION: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01108-2.
format Online
Article
Text
id pubmed-9628034
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96280342022-11-03 Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients Lennol, Matthew Paul Sánchez-Domínguez, Irene Cuchillo-Ibañez, Inmaculada Camporesi, Elena Brinkmalm, Gunnar Alcolea, Daniel Fortea, Juan Lleó, Alberto Soria, Guadalupe Aguado, Fernando Zetterberg, Henrik Blennow, Kaj Sáez-Valero, Javier Alzheimers Res Ther Research OBJECTIVE: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients. METHODS: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. RESULTS: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. CONCLUSION: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01108-2. BioMed Central 2022-11-02 /pmc/articles/PMC9628034/ /pubmed/36324176 http://dx.doi.org/10.1186/s13195-022-01108-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lennol, Matthew Paul
Sánchez-Domínguez, Irene
Cuchillo-Ibañez, Inmaculada
Camporesi, Elena
Brinkmalm, Gunnar
Alcolea, Daniel
Fortea, Juan
Lleó, Alberto
Soria, Guadalupe
Aguado, Fernando
Zetterberg, Henrik
Blennow, Kaj
Sáez-Valero, Javier
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
title Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
title_full Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
title_fullStr Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
title_full_unstemmed Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
title_short Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
title_sort apolipoprotein e imbalance in the cerebrospinal fluid of alzheimer’s disease patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628034/
https://www.ncbi.nlm.nih.gov/pubmed/36324176
http://dx.doi.org/10.1186/s13195-022-01108-2
work_keys_str_mv AT lennolmatthewpaul apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT sanchezdominguezirene apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT cuchilloibanezinmaculada apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT camporesielena apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT brinkmalmgunnar apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT alcoleadaniel apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT forteajuan apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT lleoalberto apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT soriaguadalupe apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT aguadofernando apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT zetterberghenrik apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT blennowkaj apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients
AT saezvalerojavier apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients